BrdU does not induce hepatocellular damage in experimental Wistar rats.

Area of Science:

• Biomedical research
• Toxicology
• Cell biology

Background:

• Bromodeoxyuridine (BrdU) is a thymidine analog crucial for cell proliferation and neurogenesis studies.
• Repeated administration of BrdU may impact liver function, necessitating investigation.
• Partial hepatectomy (PHx) models are used to study liver regeneration and drug effects.

Purpose of the Study:

• To assess the systemic and hepatocellular effects of multiple Bromodeoxyuridine (BrdU) administrations in a rat partial hepatectomy (PHx) model.
• To evaluate potential liver function profile changes induced by BrdU.
• To determine if BrdU causes hepatocellular damage or apoptosis post-PHx.

Main Methods:

• Male Wistar rats underwent 30% partial hepatectomy (PHx) and received BrdU (50 mg/Kg) via intraperitoneal injection at multiple time points post-surgery.
• Groups included control, sham, PHx without BrdU (PHx/BrdU(-)), and PHx with BrdU (PHx/BrdU(+)).
• Liver function markers (ALT, AST, LDH, AP, bilirubin, proteins, albumin), histopathology (hematoxylin-eosin), and apoptosis (caspase-3) were analyzed on day 16.

Main Results:

• Bromodeoxyuridine (BrdU) did not induce significant hepatocellular damage or apoptosis in male rats post-PHx.
• Multiple BrdU administrations did not cause a significant decrease in body weight.
• Elevated serum levels of alanine transferase (ALT) and lactate dehydrogenase (LDH) were observed.

Conclusions:

• Bromodeoxyuridine (BrdU) administration, even multiple times, does not appear to cause direct hepatocellular damage in this rat model.
• The observed increase in ALT and LDH suggests potential systemic effects or transient liver stress rather than direct toxicity.
• Further research is warranted to fully elucidate the systemic impact of BrdU in regenerative models.